Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors.

Trial Profile

Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Fenretinide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 14 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top